Abstract
With upcoming therapeutic approaches based on tau pathology, biomarkers of this pathology are urgently needed.1,2 In this issue of Neurology® , Mattsson and colleagues3 compared PET imaging of tau pathology with CSF measurements (total tau [t-tau] and phosphorylated tau [p-tau]), and related these measures in terms of diagnostic performance for Alzheimer disease (AD).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
